rabipur gsk kosten

Smile Train partnership Roger Connor, President, Global Vaccines at GSK, said: “This agreement with Bavarian Nordic will enable us to commit greater resources to our key growth assets and to our R&D pipeline, while also ensuring the continued supply of these important and successful vaccines.” GSK will receive an upfront payment of approximately EUR301 million (£259m) and will also receive milestone payments of EUR495 million and additional proceeds from the sale of inventory over the course of the supply arrangements for a total consideration of up to EUR 955m.

Our consumer healthcare products We are a global company delivering billions of healthcare products a year. Choose your path. Consumer Healthcare Apprentices, students and graduates

Millions of people live with unmet healthcare needs. Social media GlaxoSmithKline UK Limited Registered in England and Wales No 4310159.

The Product Information is intended to assist healthcare professionals make decisions about treatment options and provide advice on the appropriate use of a medicine to patients.

Discover our latest financial performance announcement and search for historical quarterly results materials We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare

Experienced professionals

Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting To ensure supply continuity both vaccines will continue to be manufactured primarily at GSK’s Marburg site in Germany until full production is transferred to Bavarian Nordic.

Development

Responsible business is how we do business. The transaction is expected to close by the end of 2019 and is conditional upon anti-trust approval as well as approval of Bavarian Nordic’s rights issue by its shareholders.Rabipur is a well-established life-saving vaccine (rabies virus causes acute invariable fatal disease) with 30 years of market experience supported by extensive clinical and safety evidence and WHO pre-qualification. Explore the latest news, different ways to stay in touch and available useful resources

Our prescription medicines Meet some of our employees from various roles, and find out what they really think about working life with us.

Our use of animals

It has unique dosing flexibility supported by proven efficacy and long-term persistence data.GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. Shareholder information Research and development

The value of inventory at the anticipated closing date is estimated to be EUR 159 million.

GSK to receive upfront payment of approximately EUR301 million (£259m) and milestone payments for a total consideration of up to EUR955 million (£822m)GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the divestment of travel vaccines Rabipur (tradename Rabavert in the US) for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic.The decision to divest these brands, acquired from Novartis in 2015 as part of the acquisition of its vaccines business, supports GSK’s strategic intent to increase focus and reinvest in growth assets, innovation and a simplified supply chain in its vaccines business. Operating responsibly

Tips for applying Save the Children partnership Save the Children partnership Financial calendar

Share price analysis We want to help change this, using our scientific expertise, our partnerships and our global reach. Trials in people

.